We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Agilent Technologies Acquires Dako to Expand Diagnostic Solutions Portfolio

By LabMedica International staff writers
Posted on 18 May 2012
Print article
Agilent Technologies Inc. (Agilent; Santa Clara, CA, USA), a bio-analytical technology solutions company, has announced an agreement to acquire Dako (Glostrup, Denmark), a global, tissue-based cancer diagnostic company, from the private equity group EQT (Sweden) for USD 2.2 billion in order to strengthen Agilent’s product line and offer patients and healthcare professionals improved cancer diagnostic tools and services.

Agilent's bio-analytical measurement business provides instruments, software, and services for the purpose of identifying and analyzing the physical and biological properties of substances and products. Similarly, Dako provides antibodies, reagents, scientific instruments, and software primarily to customers in pathology laboratories for faster and improved diagnostics for cancer patients. The acquisition aims to improve both companies’ services to create innovative medical and diagnostic solutions.

According to Bill Sullivan, president and CEO, Agilent, the partnership with Dako, which he describes as “one of the world's leading providers of cancer diagnostics tools,” will help create a broader range of solutions to fight cancer and improve patient care.

"Agilent's strategy in acquiring Dako is about strengthening the company's presence in life science and about revenue growth," added Mr. Sullivan. "Dako employs extremely talented people with specialized expertise that we highly value. Their knowledge and experience will be very important as we move forward together."

Lars Holmkvist, CEO, Dako, agrees that the acquisition will help advance each company’s technologies to provide improved diagnostics products.

"Our combined companies will have complementary strengths. Like Agilent, Dako has a long history as a leader in scientific advancement and a culture that values discovery and innovation. We believe that Agilent and Dako are a winning combination," added Mr. Holmkvist.


Related Links:

Agilent Technologies Inc.

Dako

EQT






Gold Member
Troponin T QC
Troponin T Quality Control
Automated Blood Typing System
IH-500 NEXT
New
Nuclear Matrix Protein 22 Test
NMP22 Test
New
Thyroxine ELISA
T4 ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.